Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. ResApp Health Limited
  6. News
  7. Summary
    RAP   AU000000RAP5


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ResApp Health : Medgate enters licence agreement with ResApp Health

08/03/2021 | 08:36pm EDT

View printer-friendly version

  • Medgate is a leading provider of digital health and telemedicine services and operates Europe's largest telemedical centre
  • Licence agreement follows the successful completion of a pilot of ResAppDx which commenced in March 2021
  • Pilot demonstrated the clinical effectiveness of ResAppDx was consistent with ResApp's clinical study results and achieved high levels of patient satisfaction

Brisbane, Australia, 4 August 2021 - ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today is pleased to announce that it has signed a commercial licence agreement with Medgate AG ('Medgate') to use ResApp's smartphone-based acute respiratory diagnostic test, ResAppDx on Medgate's telehealth platform in Europe and the Philippines.

Medgate is a leading provider of telehealth services and since 2000 has operated the largest telemedical centre run by doctors in Europe. The group employs over 510 people worldwide, including over 200 physicians.

ResAppDx is ResApp's acute respiratory diagnostic test that uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. It is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia.

The agreement follows a successful pilot of ResAppDx across Medgate's telemedicine services, which confirmed the benefits of ResAppDx for clinicians and patients (refer ASX announcements 9 November 2020, 4 March 2021 and 3 June 2021). The clinical data observed in the pilot was found to be consistent with the strong performance data from ResApp's extensive clinical studies.

CEO and Managing Director, Dr Tony Keating said: 'Medgate is a long-standing, global leader in telehealth and we are pleased to enter into a commercial licence agreement that provides ResAppDx for the benefit of their clinicians and patients. We are delighted to secure our first commercial telehealth license agreement in Europe and receive a positive endorsement of ResAppDx by such a successful leader in the telehealth field.

'We are very appreciative of the ongoing support, collaborative partnership and key insights provided by the expert team at Medgate and look forward to working with them over the long term.'

Dr Andy Fischer, CEO Medgate said: 'ResApp Health has proven to be a high value partner and their ResAppDx technology has helped us to enhance our high standards of medical care and patient safety. Importantly we've had a very positive response to ResAppDx from our patients, they can perform the test easily, understand the rationale and see immediate benefit in their telehealth consultation with our clinician. We are absolutely convinced that the use of new technologies like ResAppDx will enable an advancement of our digital health platform.'

Agreement details:
Medgate and ResApp Health have entered into a Licence Agreement ('Agreement') where ResApp licenses the ResAppDx software development kit (SDK) to Medgate for their non-exclusive use in Europe and the Philippines. The Agreement is for an initial one-year term. Either party may terminate the Agreement by giving 30 days notice. The Agreement specifies pricing on a monthly subscription basis. At this point in time, ResApp does not anticipate this Agreement to have a material impact on its operating results.


About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

About Medgate AG
Medgate brings the physician to where he or she is needed by patients and relies on Digital Health solutions to do so. The focus is on the well-being of the patient and the benefits to society. Medgate was founded in Switzerland in 1999 and today employs over 510 people worldwide. Since 2000, Medgate has been operating the largest medical telemedicine center in Europe and thus has an extraordinary amount of experience and knowledge in telemedicine. Medgate is also present in Germany and the Philippines. www.medgate.care


ResApp Health Limited published this content on 04 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2021 00:35:06 UTC.

ę Publicnow 2021
09/19RESAPP HEALTH : Recruits First Patients in India in COVID-19-Related Cough Sounds Study
09/19RESAPP HEALTH : First patients recruited in COVID-19 clinical study in India
09/19Resapp Health Limited Announces First Patients Recruited in Covid-19 Clinical Study in ..
09/14RESAPP HEALTH : Gets Regulatory Nod for R&D Rebate; Shares Fall 6%
09/13RESAPP HEALTH : receives Advanced and Overseas R&D finding
09/13ResApp Health Limited Receives Advanced and Overseas R&D Finding
09/01RESAPP HEALTH : Secures Indonesian Regulatory Approval for Diagnostic App
08/31RESAPP HEALTH : ResAppDx receives regulatory approval in Indonesia
08/31ResApp Health Limited Receives Regulatory Approval in Indonesia
08/26ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2021
More news
Sales 2021 0,07  0,05  0,05 
Net income 2021 -6,77 M -4,93 M -4,93 M
Net cash 2021 6,40 M 4,66 M 4,66 M
P/E ratio 2021 -4,71x
Yield 2021 -
Capitalization 64,4 M 46,9 M 46,9 M
EV / Sales 2020 -
EV / Sales 2021 413 455 192x
Nbr of Employees 500
Free-Float 84,4%
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Tony Keating Chief Executive Officer, Executive Director & MD
Al Rey Lunar Vice President-Finance
Roger Aston Non-Executive Chairman
Christopher Ntoumenopoulos Non-Executive Director
Brian Leedman Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SNAP INC.59.94%127 394
ANGI INC.-1.17%6 575
GRUBHUB INC.-19.36%5 591
PERFECT WORLD CO., LTD.-47.59%4 794